<DOC>
	<DOCNO>NCT00204438</DOCNO>
	<brief_summary>We hypothesize administration OCs vary follicular diameter provide appropriate model study follicular atresia woman . Clinically , hypothesize administration OCs different stage follicular phase result markedly different pattern follicular development and/or atresia .</brief_summary>
	<brief_title>Administration Oral Contraceptives Different Times Follicular Phase Menstrual Cycle</brief_title>
	<detailed_description>This study single-centre , randomize , open-label , double-controlled protocol study pattern ovarian follicular growth regression woman administer 0.15mg desogestrel /0.03mg ethinyl estradiol different stage follicular phase menstrual cycle . We track growth regression dominant follicle administration OC mean highly sophisticated transvaginal ultrasonography computerize image analysis technique . The extremely high resolution ultrasonography ovarian follicles computer-assisted image analysis unique Women 's Health Imaging Research Laboratory ( WHIRL ) University Saskatchewan . The synergyne ( Â© R.A. Pierson ) image analysis program develop WHIRL ability allow assessment physiologic status follicles small 6 10 mm . This unique protocol allow u characterize pattern follicular growth atresia suppressive effect oral contraception , well assessment anovulatory follicle may develop OCs administer advanced stage follicular development . The work hypothesis administration monophasic OCs prior time physiologic selection dominant follicle prevent development ovulatory follicle ( selection occur dominant follicle reach 10mm [ Baerwald &amp; Pierson , unpublished data ] ) . In addition , hypothesize administration OCs selection dominant follicle , advance stage follicular development result 1 4 scenario : 1 . ) Ovulation dominant follicle , 2 . ) Regression dominant follicle , 3 ) . Formation Hemorrhagic Anovulatory follicle ( HAF ) Luteinized Unruptured Follicle ( LUF ) , 4 . ) Formation follicular cyst . We hypothesize atresia dominant follicle formation anovulatory follicular structure associate limited endometrial development . In test hypothesis , determine OCs safely effectively administer time follicular phase menstrual cycle . This study evaluate ovarian uterine response administration combine dose 0.15mg desogestrel /0.03mg ethinyl estradiol 1 3 different stage follicular phase menstrual cycle . The objective trial : - Develop new user-friendly administration scheme OC use ; - Use administration OCs different stage follicular development woman model study follicular atresia ; - Assess difference kinetics , physiologic status ( state viability atresia ) , ultrasonographic image attribute follicle grow , regress , ovulate , form anovulatory follicular structure administration exogenous steroid hormone ; - Assess endometrial response ovarian suppression ultrasonographic evaluation endometrial thickness endometrial pattern . After screen measurement confirm subject eligibility , subject randomize initiate OC therapy one three different time menstrual cycle : Experimental Group # 1 : receives OCs dominant follicle reach 10mm Experimental Group # 2 : receives OCs dominant follicle reach 14mm Experimental Group # 3 : receives OCs dominant follicle reach 18mm Fifteen woman randomize 3 experimental group stratify design scheme . Data collect ongoing OC trial ( BMC # 2000-169 ) serve OC control data ( n=15 ) . Data collect previous study ( BMC # 1988-80 ) serve natural cycle control data ( n=60 ) .</detailed_description>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Desogestrel</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<criteria>Female volunteer childbearing potential ; Are first time user OCs discontinue OCs least 1 month prior study entry ; Aged 18 35 year ( extremes include ) ; Normal body mass index ( 1838 ) ; Has sign inform consent form ; Is good health confirm medical history , physical examination , PAP smear colposcopy within past 12 month normal result . Any contraindication oral contraceptive use ; Irregular menstrual cycle Ultrasonographic evidence ovarian dysfunction , Polycystic Ovary Syndrome ( PCOS ) ; Pregnancy ( suspect diagnose ) lactation ; Use disallow concomitant therapy ; History suspicion drug alcohol abuse ; Participation investigational drug trial within 30 day prior selection ; Exhibits disorder contraindication steroid hormonal therapy , include , example , follow condition : History , actual , thrombophlebitis thromboembolic disorder ; History , actual , cerebrovascular disorder ; History , actual , myocardial infarction coronary artery disease ; Acute liver disease ; History , actual , benign malignant liver tumor ; Known , suspect , carcinoma breast ; Known , suspect , estrogendependent neoplasia ; Undiagnosed abnormal vaginal bleeding ; Any ocular lesion arise opthalmic vascular disease , partial complete loss vision defect visual field . Latex allergy .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>female contraception</keyword>
	<keyword>oral contraceptive</keyword>
	<keyword>emergency contraceptive</keyword>
	<keyword>ovary</keyword>
	<keyword>follicle</keyword>
	<keyword>ovulation</keyword>
</DOC>